Inhibition product formation polymorphonuclear cell degranulation tenidap sodium patients rheumatoid arthritis effect tenidap sodium new antiinflammatory/antirheumatic drug mg/day days eicosanoid production neutrophil degranulation patients rheumatoid arthritis Endogenous prostaglandin levels ex vivo production leukotriene synovial fluid samples baseline week peripheral blood polymorphonuclear cell PMN degranulation surface-bound IgG stimulation possible product-mediated event lactoferrin elastase release culture fluid decreased levels endogenous prostaglandin radioimmunoassay ex vivo production PMN high performance liquid chromatography synovial fluid samples patients tenidap Release granule lactoferrin elastase PMN patients tenidap PMN vitro tenidap Improvement clinical measures biochemical changes unique inhibitory property tenidap production degranulation clinical activity nonsteroidal antiinflammatory drugs 